ייעוץ חוות דעת בנושא 2 חומרים(תמונות בפנים)

[guysudri2]

אני כבר בשבוע 3
לוקח 250 טסט , 250 בולדנון , 2 זריקות בשבוע = 500
לא מרגיש שינוי לא בכוח ולא במראה, האמנם עליתי בסביבות ה4 קילו(משתמש בגיינר ואוכל המון)

הינה שני החומרים

http://www.siz.co.il/my/gz5wcunyx3md.jpg


http://www.siz.co.il/my/t4ofinumt3wm.jpg


השאלות שלי האם החומרים האלו מוכרים, טובים ואיכותיים ומה הרמה שלהם, שלא מכרו לי זבל.
והאם הסייקל שאני עושה בסדר מבחינת מינונים(סייקל ראשון)

 

[Mishel Mishayev]

שימוש ב-AAS לרוב מחליש את מערכת החיסון, אצל אנשים שלרוב רגישים להורמונים חיצונים, ישנה הסתברות גבוהה יותר לחלות במחלות ויראליות שונות. בדרך כלל ניתן לאבחן את הרגשיות בלחפש בהיסטוריה אם בעבר היו מקרים של test flu, לאותם האנשים בהחלט היתי ממליץ להימנע מהעמסות. זה שאנחנו יודעים את זמני מחצית החיים זה עדיין לא אומר הרבה, תנודות קיצוניות של הורמונים בדם בהחלט לא מומלצים, מערכת האנדוקרינית מאוד מסובכת, כל תנודה בהורמון אחד מביא השלכות להורמונים נוספים, ככל שיש יותר תנודות קיצוניות ככה יש יותר תופעות לוואי. זה אחד הסיבות שמנסים תמיד לשמור על רמות יציבות בדם, ולפי אסטר קובעים תדירות הזריקות. כשעושים העמסה, די קשה לפגוע בול, לרוב מה שקורה מגיעים די מהר לרמות גבוההות ואז יש צניחה ומזה רצוי להימנע.

Central European Journal of Biology
March 2009, Volume 4, Issue 1, pp 19-33
Anabolic androgenic steroids effects on the immune system: a review

• Sonya Marshall-Gradisnik,
• Rachel Green,
• Ekua W. Brenu,
• Robert P. Weatherby

* Final gross prices may vary according to local VAT.

Get Access

Abstract
Androgenic anabolic steroids (AAS) are synthetic derivatives of the male hormone testosterone. AAS are used by athletes and recreational users of all ages to enhance their athletic performance and/or physical appearance. While several adverse effects of AAS abuse have been described, their effect on the immune system has not been clearly elucidated. The literature generally indicates that supraphysiologic doses of AAS with an intact steroid nucleus are immunosuppressive, that is they reduce immune cell number and function. While those with alterations to the steroid nucleus are immunostimulatory as they induce the proliferation of T cells and other immune cells. Specifically, several common AAS have been shown to adversely influence lymphocyte differentiation and proliferation, antibody production, Natural Killer Cytotoxic activity and the production of certain cytokines, thereby altering the immune reaction. These effects may be profound and long lasting depending on the dosing regime, types or combinations of AAS used and the extent and duration of AAS abuse. Nevertheless, the effects of long term use of supraphysiologic doses of AAS on the immune system remain uncertain.



​

1. Hoberman J., Yesalis C., The history of synthetic testosterone, Scientific America​
2. n 1995, 272, 76–81 CrossRef​
3. Ariel G., Saville W., Anabolic steroids: the physiological effects of placebos, Med. Sci. Sports, 1972, 4, 124–126​
4. Cicero T.J., O’Connor L.H., Abuse liability of anabolic steroids and their possible role in the abuse of alcohol, morphine and other substances, In: Lin G.C., Erinoff L. (Eds.), Anabolic steroid abuse, National Institute on Drug Abuse, Rockville, 1990​
5. Kadi F., Adaptation of human skeletal muscle to training and anabolic steroids, Acta Physiol. Scand. Suppl., 2000, 646, 1–52​
6. Kadi F., Eriksson A., Holmner S., Thornell L., Effects of anabolic steroids on the muscle cells of strength trained athletes, Med. Sci. Sports. Exerc., 1999, 31, 1528–1534​
7. Giorgi A., Weatherby R.P., Murphy P., Muscular strength, body composition and health responses to the use of testosterone enanthate: a double blind study, J. Sci. Med. Sport, 1999, 2, 341–355​
8. Rogerson S., Weatherby R.P., Deakin G.B., Meir R.A., Coutts R.A., Zhou S., et al., The effect of short-term use of testosterone enanthate on muscular strength and power in healthy young men, J. Strength Cond. Res., 2007, 21, 354–361​
9. van Marken Lichtenbelt W.D., Hartgens F., Vollaard N.B., Ebbing S., Kuipers H., Bodybuilders’ body composition: effect of nandrolone decanoate, Med. Sci. Sports. Exerc., 2004, 36, 484–489​
10. Berning J.M., Adams K.J., Stamford B.A., Anabolic steroid usage in atheletics: fact, fiction, and public relations, J. Strength Cond. Res., 2004, 18, 908–917​
11. Yesalis C.E., Use of steroids for self-enhancement: an epidemiologic/societal perspective, AIDS Read., 2001, 11, 157–160​
12. Shah K., Montoya C., Persons R., Do testosterone injections increase libido for elderly hypogonadal patients?, J. Fam. Pract., 2007, 56, 301–305​
13. Johnston L.D., O’Malley P.M., Bachman J.G., Schulenberg J.E., Monitoring the future national results on adolescent drug use: Overview of Key Findings, 2005, (NIH Publication No. 06-5882), National Institute on Drug Abuse, Bethesda, 2006​
14. Drug Enforcement Administration, ARCOS Data for Selected Opioid Analgesics, 1980–1996, Arlington, US Dept of Justice, 1997​
15. Yesalis C., Kennedy N., Kopstein A., Bahrke M., Anabolic-androgenic steroid use in the United States, JAMA, 1993, 270, 1217–1221​
16. Hameed A., Brothwood T., Bouloux P., Delivery of testosterone replacement therapy, Curr. Opin. Invest. Drugs, 2003, 4, 1213–1219​
17. Snyder P.J., Lawrence D.A., Treatment of male hypogonadism with testosterone enanthate, J. Clin. Endocrinol. Metab., 1980, 51, 1335–1339 CrossRef​
18. Ajayi A.A.L., Mathur R., Halushka P.V., Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses, Circulation, 1994, 91, 2742–2747​
19. Bross R., Javanbakht M., Bhasin S., Anabolic interventions for aging associated Sarcopenia, J. Clin. Endocrinol. Metab., 1999, 84, 3420–3430​
20. Kuhn C.M., Anabolic Steroids, Recent. Prog. Horm. Res., 2002, 57, 411–434​
21. Pardridge W., Serum bioavailability of sex steroid hormones, Clin. Endocrinol. Metab., 1986, 15, 259–278​
22. Rannevik G., Jeppsson S., Johnell O., Bjerre B., Laurell-Borulf Y., Svanberg L., A longitudinal study of the perimenopausal transition: altered profiles of steroid and pituitary hormones, SHBG and bone mineral density, Maturitas, 1995, 21, 103–113​
23. Wilson J., Androgen abuse by athletes, Endocr. Rev., 1988, 9, 181–199​
24. Bartsch W., Anabolic steroids: action on cellular level, In: Kopera H. (Ed.) Anabolic androgenic steroids towards the year 2000, Blackwell, Vienna, 1993​
25. Creutzberg E., Schols A., Anabolic steroids, Curr. Opin. Clin. Nutr. Metab. Care, 1999, 2, 243–253​
26. Horton R., Markers of peripheral androgen action in vivo and in vitro, Clin. Dermatol., 1988, 6, 46–51​
27. Falkenstein E., Tillmann H.-C., Christ M., Feuring M., Wehling M., Multiple Actions of Steroid Hormones-A Focus on Rapid, Nongenomic Effects, Pharmacol. Rev., 2000, 52, 513–556​
28. Beato M., Gene regulation by steroid hormones, Cell, 1989, 56, 335–344​
29. Beato M., Klug J., Steroid hormone receptors: An update, Hum. Reprod. Update, 2000, 6, 225–236​
30. Scheidereit C., Geisse S., Westphal H., Beato M., The glucocorticoid receptor binds to defined nucleotide sequences near the promoter of mouse mammary tumor virus, Nature (Lond.), 1983, 304, 749–752​
31. Beato M., Chavez S., Truss M., Transcriptional regulation by steroid hormones, Steroids, 1996, 61, 240–251​
32. Kindler S., Wang H., Richter D., Tiedge H., RNA transport and local control of translation, Ann. Rev. Cell Dev. Biol., 2005, 21, 223–245​
33. Godowski P., Picard D., Steroid receptors. How to be both a receptor and a transcription factor, Biochem. Pharmacol., 1989, 38, 3135–3143​
34. Chang C., Saltzman A., Yeh S., Young W., Keller E., Lee H., et al., Androgen receptor: an overview, Crit. Rev. Eukaryotic Gene. Expr., 1995, 5, 97–125​
35. Wilson J., Androgens, In: Hardman J., Limbird L. (Eds.), Goodman and Gilman’s the pharmacological basis of therapeutics, 9th ed., McGraw-Hill, New York, 1996​
36. Boonyaratanakornkit V., Edwards D., Receptor mechanisms mediating non-genomic actions of sex steroids, Semin. Reprod. Med., 2007, 25, 139–153​
37. Wunderlich F., Benten W., Lieberherr M., Guo Z., Stamm O., Wrehlke C., et al., Testosterone signaling in T cells and macrophages, Steroids, 2002, 67, 535–538​
38. Kovacs W., Olsen N., Androgen receptors in human thymocytes, J. Immunol., 1987, 139, 490–493​
39. Benten W.P.M., Lieberherr M., Giese G., Wrehlke C., Sekeris C.E., Mossmann H., et al., Functional testosterone receptors in plasma membranes of T cells, FASEB, 1999, 13, 123–133​
40. Machelon V., Nome F., Tesarik J., Nongenomic effects of androstenedione on human granulosa cells in relation to luteinization process, J. Clin. Endocrinol. Metab., 1998, 83, 263–269​
41. Gametchu B., Watson C., Pasko D., Size and steroid binding characterisation of membrane associated glucocorticoid receptor in S49 lymphoma cells, Steroids, 1991, 56, 411–419​
42. Wehling M., Specific, nongenomic actions of steroid hormones, Annu. Rev. Physiol., 1997, 59, 365–393​
43. Farnsworth W., The prostate plasma membrane as an androgen receptor, Membr. Biochem., 1990 9, 141–162​
44. Sheridan P., Can a single androgen receptor fill the bill?, Mol. Cell Endocrinol., 1991, 76, C39–C45​
45. Lieberherr M., Grosse B., Androgens increase intracellular calcium concentration and inositol 1,4,5-trisphosphate and diacylglycerol formation via a pertussis toxin-sensitive G-protein, J. Biol. Chem., 1994, 269, 7217–7223​
46. Hurd R., Testosterone, US National Library of Medicine and National Institutes of Health, Bethesda, 2006​
47. Mutzebaugh C., Does the choice of alpha-AAS really make a difference?, HIV Hotline, 1998, 8, 10–11​
48. Yamamoto Y., Moore R., Hess H., Guo G., Gonzalez F., Korach K., et al., Estrogen receptor alpha mediates 17alpha-ethynylestradiol causing hepatotoxicity, J. Biol. Chem., 2006, 281, 16625–16631​
49. Brodsky I., Balagopal P., Nair K., Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men—a clinical research center study, J. Clin. Endocrinol. Metab., 1996, 81, 3469–3475​
50. Joumaa W.H., Leoty C., Differential effects of nandrolone decanoate in fast and slow rat skeletal muscles, Med. Sci. Sports Exerc., 2001, 33, 397–403​
51. Sinha-Hikim I., Artaza J., Woodhouse L., Gonzalez-Cadavid N., Singh A., Lee M., et al., Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy, Am. J. Physiol. Endocrinol. Metab., 2002, 283, E154–E164​
52. Berger J., Pall L., Hall C., Simpson D., Berry P, Dudley R., Oxandrolone in AIDS-wasting myopathy, AIDS, 1996, 10, 1657–1662​
53. Hughes T.K., Fulep E., Juelich T., Smith E.M., Stanton G.J., Modulation of immune responses by anabolic androgenic steroids, Int. J. Immunopharmacol., 1995, 17, 857–863​
54. Aribarg A., Sukcharoen N., Chanprasit Y., Ngeamvijawat J., Kriangsinyos R., Suppression of spermatogenesis by testosterone enanthate in Thai men, J. Med. Assoc. Thai.,1996, 79, 624–629​
55. Matsumoto A., Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production, J. Clin. Endocrinol. Metab., 1990, 70, 282–287​
56. Ballal S., Domoto D., Polack D., Marciulonis P., Martin K., Androgens potentiate the effects of erythropoietin in the treatment of anemia of endstage renal disease, Am. J. Kidney Dis., 1991, 17, 29–33​
57. Berns J., Rudnick M., Cohen R., Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease, Am. J. Kidney Dis., 1991, 18, 143​
58. Berns J., Rudnick M., Cohen R., A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis, Clin. Nephrol., 1992, 37, 264–267​
59. Wu F., Farley T., Peregoudov A., Waites G., Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. World Health Organization Task Force on Methods for the Regulation of Male Fertility, Fertil. Steril., 1996, 65, 626–636​
60. Bhasin S., Storer T., Berman N., Callegari C., Clevenger B., Phillips J., et al., The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men, N. Engl. J. Med., 1996, 335, 1–7​
61. Calfee R., Fadale P., Popular ergogenic drugs and supplements in young athletes, Pediatrics, 2006, 117, 577–589​
62. Velazquez I., Alter B., Androgens and liver tumors: Fanconi’s anemia and non-Fanconi’s conditions, Am. J. Hematol., 2004, 77, 257–267​
63. Strauss R., Yesalis C., Anabolic steroids and the athlete, Annu. Rev. Med., 1991, 42, 449–457​
64. Bagatell C., Knopp R., Vale W., Rivier J., Bremner W., Physiologic testosterone levels in normal men suppress high-density lipoprotein cholesterol levels, Ann. Intern. Med., 1992, 116, 967–973​
65. De Piccoli B., Giada F., Benettin A., Sartori F., Piccolo E., Anabolic steroid use in body builders: an echocardiographic study of left ventricle morphology and function, Int. J. Sports Med., 1991, 12, 408–412​
66. Sullivan M., Martinez C., Gallagher E., A trial fibrillation and anabolic steroids, J. Emerg. Med., 1999, 17, 851–857​
67. Dickerman R., Schaller F., McConathy W., Left ventricular wall thickening does occur in elite power athletes with or without anabolic steroid use, Cardiology, 1998, 90, 145–148​
68. Palacios A., McClure R., Campfield A., Swerdloff R., Effect of testosterone enanthate on testis size, J. Urol., 1981, 126, 46–48​
69. Alén M., Androgenic steroid effects on liver and red cells, J. Sports Med., 1985, 19, 15–20​
70. Marcus R., Korenman S., Estrogens and the human male, Annu. Rev. Med., 1976, 27, 357–370​
71. Hartgens F., Kuipers H., Effects of androgenicanabolic steroids in athletes, Sports Med., 2004, 34, 513–554​
72. Manikkam M., Crespi E., Doop D., Herkimer C., Lee J., Yu S., et al., Fetal programming: prenatal testosterone excess leads to fetal growth retardation and postnatal catch-up growth in sheep, Endocrinology, 2004, 145, 790–798​
73. Corrigan B., Anabolic steroids and the mind, MJA, 1996, 165, 222–226​
74. Midgley S., Heather N., Davies J., Levels of aggression among a group of anabolic-androgenic steroid users, Med. Sci. Law., 2001, 41, 309–314​
75. Casavant M., Blake K., Griffith J., Yates A., Copley L., Consequences of use of anabolic androgenic steroids, Pediatr. Clin. North Am., 2007, 54, 677–690​
76. Medras M., Tworowska U., Treatment strategies of withdrawal from long-term use of anabolicandrogenic steroids, Pol. Merkur. Lekarski, 2001, 11, 535–538​
77. Kruisbeek A.M., Development of alphabeta T cells, Curr. Opin. Immunol., 1993, 5, 227–234​
78. Abbas A.K., Murphy K.M., Sher A., Functional diversity of helper T lymphocytes, Nature, 1996, 383, 787–793​
79. Springer T.A., Adhesion receptors of the immune system, Nature, 1990, 6, 425–434​
80. Mosmann T.R., Coffman R.L., TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties, Annu. Rev. Immunol., 1989, 7, 145–173​
81. Alam R., A brief review of the immune system, Prim. Care, 1998, 25, 727–738​
82. Medana I.M., Gallimore A., Oxzenius A., Martinic M.M., Wekerle H., Neumann H., MHC class I —restricted killing of neurons by virus-specific CD8+T lymphocytes is effected through the Fas/FasL, but not the perforin pathway, Eur. J. Immunol., 2000, 30, 3623–3633​
83. Sutton B.J., Immunoglobulin structure and function: the interaction between antibody and antigen, Curr. Opin. Immunol., 1989, 2, 106–113​
84. Fanning L.J., Connor A.M., Wu G.E., Development of the immunoglobulin repertoire, Clin. Immunol. Immunopathol., 1996, 79, 1–14​
85. Ward E.S., Ghetie V., The effector function of immunoglobulins: implications for therapy, Ther. Immunol., 1995, 2, 77–94​
86. Clark M.R., IgG effector mechanisms, Chem. Immunol., 1997, 65, 88–110​
87. Hamerman J.A., Ogasawara K., Lainer L.L., NK cells in innate immunity, Curr Opin. Immunol., 2005, 17, 29–35​
88. Farag S.S., Fehniger T.A., Ruggeri L., Velardi A., Caligiuri M.A., Natural killer cell receptors: new biology and insights into the graft-versus-leukaemia effect, Am. Soc. Hematol., 2002, 100, 1935–1947​
89. Viver E., Tomasello E., Baratin M., Walzer T., Ugolini S., Functions of natural killer cells, Nature Immunol., 2008, 9, 503–510​
90. Cooper M.A., Bush J.E., Fehniger T.A., VanDeusen J.B., Waite R.E., Liu Y., et al., In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells, Blood, 2002, 100, 3633–3638​
91. Freud A.G., Caligiuri M.A., Human Natural Killer cell development, Immunol. Rev., 2006, 214, 56–72​
92. Scott G.B., Meade J.L., Cook G.P., Profiling killers; unravelling the pathways of human natural killer cell function, Brief Funct. Genomic Proteomic, 2008, 7, 8–16​
93. Dinarello C.A., Proinflammatory Cytokines, Chest, 2000, 118, 503–508​
94. Opal S.M., DePalo V.A., Anti-inflammatory cytokines, Chest, 2000, 117, 1162–1172​
95. Grossman C.J., Regulation of the immune system by sex steroids, Endocr. Rev., 1984, 5, 435–455​
96. Grossman C.J., Interactions between gondal steroids and the immune system, Science, 1985, 227, 257–261​
97. Grossman C.J., Roselle G.A., The control of immune response by endocrine factors and the clinical significance of such regulation, Prog. Clin. Biochem. Med., 1987, 4, 1–56​
98. Sthoeger Z.M., Chiorazzi N., Lahita R.G., Regulation of the immune response by sex hormones: I. In vitro effects of estradiol and testosterone on pokeweed mitogen-induced human B cell differentiation, J. Immunol., 1988, 141, 91–98​
99. Abraham A., Bug G., 3H-testosterone distribution and binding in rat thymus cells in vivo, Mol. Cell Biochem., 1976, 13, 157–163​
100. Besedovsky H.O., Del Rey A., Immune-Neuro-Endocrine Interactions: Facts and Hypotheses, Endocr. Rev., 1996, 17, 64–102​
101. Landmann R., Wesp M., Box R., Keller U., Buhler F., Distribution and function of beta-adrenergic receptors in human blood lymphocytes, In: Hadden J., Masek K., Nistico G. (Eds.), Interactions among CNS, Neuroendocrine and Immune Systems, Pythagora Press, Rome, 1989​
102. Deschaux P., Paucod J.-C., Ardail D., Interaction between thymosin, testosterone and estradiol on natural killer cell activity in mice, Tohoku J. Exp. Med., 1982, 136, 367–372.​
103. Fujii H., Nawa Y, Tsuchiya H., Matsuno K., Fukumoto T,. Fukuda S., et al., Effect of a single administration of testosterone on the immune response and lymphoid tissues in mice, Cell. Immunol., 1975, 20, 315–326​
104. Mendenhall C.L., Grossman C.J., Roselle G.A., Hertelendy Z., Ghosn S.J., Lamping K., et al., Anabolic Steroid Effects on Immune Function: Differences between analogues, J. Steroid Biochem. Molec. Biol., 1990, 37, 71–76​
105. Kotani M., Nawa Y., Fujii H., Inhibition by testosterone of immune reactivity and of lymphoid regeneration in irradiated and marrow reconstituted mice, Experientia, 1974, 30, 1343–1345​
106. Weinstein Y., Berkovich Z., Testosterone effect on bone marrow, thymus and suppressor T cells in the (NZB x NZW) F1 mice: its relevance to autoimmunity, J. Immunol., 1981, 1126, 998–1002​
107. Deschaux P., Ulrich T., Goldstein A.L., In vitro effects of thymosin, testosterone and growth hormone on antibody formation in murine spleen cells, Thymus, 1, 287–291​
108. Malcolmson C., Satra C., Kantaria S., Sidhu A., Lawrence M.J., Effect of oil on the level of solubilization of testosterone propionate into oil-in-water microemulsions, J. Pharm. Sci., 1997, 87, 109–116​
109. Cummings E.A., Salisbury S.R., Givner M.L., Rittmaster R.S., Testolactone-associated high androgen levels, a pharmacologic effect or a laboratory artefact?, J. Clin. Endocrinol. Metab., 1998, 83, 784–787​
110. Rogol A.D., Yesalis C.E., Anabolic-androgenic steroids and athletes: what are the issues?, J. Clin. Endocrinol. Metab., 1992, 74, 465–469​
111. Bouman A., Jan Heineman M., Fass M.M., Sex hormones and the immune response in humans, Hum. Reprod. Update, 2005, 11, 411–423​
112. Lahita R.G., Sex steroids and rheumatic disease, Arthritis Rheum., 1985, 28, 121–126​
113. Hirota Y., Suzuki T., Chayano Y., Bito Y., Humoral immune responses characteristic of testosterone-propionate-treated chickens, Immunology, 1976, 30, 341–348​
114. Olsen N.J., Kovacs W.J., Gonadal steroids and immunity, Endocr. Rev., 1996, 17, 369–384​
115. Paavonen T., Hormonal regulation of immune responses, Ann. Med., 1994, 26, 255–258​
116. Schuurs A.H., Verheul A.M., Schot L., Experimental work with anabolics in autoimmunity models, Acta Physiol., 1985, 271, 97–107​
117. Schuurs A.H., Verheul H.A.M., Effects of gender and sex steroids on the immune response, J. Steroid Biochem., 1990, 35, 157–172​
118. Calabrese L.H., Kleiner S.M., Barna B.P., Skibinski C.I, Kirkendall D.T., Lahita R.G., et al., The effects of anabolic steroids and strength training on the human immune response, Med. Sci. Sport Exerc., 1989, 21, 386–392​
119. Siiteri P., Stites D., Immunologic and endocrine interrelationships in pregnancy, Biol. Reprod., 1982, 26, 1–14​
120. Siiteri P.K., Jones L.A., Roubinian J.R., Talal N.K., Sex steroids and the immune system: I. Sex difference in autoimmune disease in NZB/NZW hybrid mice, J. Steroid Biochem., 1980, 12, 425–432​
121. Sulke A.N., Jones D.B., Wood P.J., Hormonal modulation of human natural killer cell activity in vitro, J. Reprod Immunol., 1985, 7, 105–110​
122. Wyle F., Kent J., Immunosuppresion by sex steroid hormones. I. The effect upon PHA and PPD stimulated lymphocytes, Clin. Exp. Immunol., 1977, 27, 407–415​
123. Kanda N., Tsuchida T., Tamaki K., Testosterone inhibits immunoglobulin production by human peripheral blood mononuclear cells, Clin. Exp. Immunol., 1996, 106, 410–415​
124. Olsen N., Kovacs W., Effects of androgens on T and B lymphocyte development, Immunol. Res., 2001, 23, 281–288​
125. Hinterberger W., Vierhapper H., Anabolic steroids and blood cell production, Wien Med. Wochenschr., 1993, 143, 380–382​
126. Hervey G., Hutchinson I., Knibbs A., Burkinshaw L., Jones P., Norgan N., et al., “Anabolic” effects of methandienone in men undergoing athletic training, Lancet, 1976, 2, 699–702​
127. Hervey G., Knibbs A., Burkinshaw L., Morgan D., Jones P., Chettle D., et al., Effects of methandienone on the performance and body composition of men undergoing athletic training, Clin. Sci. (Lond.), 1981, 60, 457–461​
128. Johnson L., Roundy E., Allsen P., Fisher A., Silvester L., Effect of anabolic steroid treatment on endurance, Med. Sci. Sports., 1975, 7, 287–289​
129. Stromme S., Meen H., Aakvaag A., Effects of an androgenic-anabolic steroid on strength development and plasma testosterone levels in normal males, Med. Sci. Sports, 1974, 6, 203–208​
130. Win-May M., Mya-Tu M., The effect of anabolic steroids on physical fitness, J. Sports Med. Phys. Fitness, 1975, 15, 266–271​
131. Alén M., Reinilä M., Vihko R., Response of serum hormones to androgen administration in power athletes, Med. Sci. Sports Exerc., 1985, 17, 354–359​
132. Hartgens F., Hamulyak K., Pernot C., Willems S.M., Effects of high doses androgenic-anabolic steroids on haematoglic parameters in bodybuilders, In: 8th FIMS European Sports Medicine Congress, Granada, 1995​
133. Callewaert D.M., Moudgil V.K., Radcliff G., Waite R., Hormone specific regulation of natural killer cells by cortisol: Direct inactivation of the cytotoxic function of cloned human NK cells without an effect on cellular proliferation, FEBS Lett., 1991, 285, 108–110​
134. Marshall-Gradisnik S., Rogerson S., Zhou S., Coutts R., Meir R. Deakin G., et al., A reduction in natural killer cell cytotoxic activity after six weeks of testosterone administration, J. Exerc. Sci. Fitness., 2008, 6, 142–151​
135. Zajac A., Jarzabek R., Waskiewicz Z., The diagnostic value of the 10- and 30-second Wingate test for competitive athletes, J. Strength Cond. Res., 1999, 13, 16–19​
136. Huber S., Job L., Auld K., Influence of sex hormones on Coxsackie B-3 virus infection in Balb/c mice, Cell. Immunol., 1982, 67, 173–189​
137. Araneo B.A., Dowell T., Diegel M., Daynes R.A., Dihydrotestosterone exerts a depressive influence on the productioni of interleukin-4 (IL-4), IL-5, and gamma interferon, but not IL-2 by activated murine T cells, Blood, 1991, 78, 688–699​
138. Shephard R.J, Rhind S., Shek P.N., Exercise and the immune system: natural killer cells, interleukins and related responses, Sports Med., 1994, 18, 340–369​
139. Suzuki R., Handa K., Itoh K., Kumagai K., Natural killer cells (NK) as a responder to interleukin-2 (IL-2), I: proliferative response and establishment of cloned cells, J. Immunol., 1983, 130, 981–987​
140. Graham H., Douglas R., Ryan P., Stress and acute respiratory infection, Am. J. Epidemiol., 1986, 124, 389–401​
141. Nagao F., Suzuki M., Taeda K., Yagita H., Okumura K., Mobilisation of NK cells by exercise: down modulation of adhesion molecules on NK cells by catecholamines, Am. J. Physiol., 2000, 289, R1251–R1256​
142. Nagler A., Lainer L., Phillips J., Constitutive expression of high affinity IL-2 receptors on human CD16 natural killer cells in vivo, J. Exp. Med., 1990, 171, 1527–1533​
143. Menard C., Harlan R., Up-regulation of androgen receptor immunoreactivity in the rat brain by androgenic-anabolic steroids, Brain Res., 1993, 622, 226–236​
144. Hughes T.K., Rady P.L., Smith E.M., Potential for the effects of anabolic steroid abuse in the immune and neuroendocrine axis, J. Neuroimmunol., 1998, 83, 162–167​
145. World Anti-Doping Agency. The World Anti-Doping Code, The 2008 prohibited list, 2008, http://www.wada-ama.org/rtecontent/document/2008_List_En.pdf​
146. Kicman A.T., Pharmacology of anabolic steroids, Br. J. Pharmacol., 2008, 154, 502–521​

 

[SPF]

בסדר לא מתבייש להגיד שאכלתי אותה הפעם , לומדים.

סייקל הבא הולך לנסות חברה חדשה שנקראת פארמה לאב שמעתי שהיא מטורפת.

פארמה לאב? עוד חברה מפוקפקת שאין לה אבא ואמא ומיוצרת בארץ בתתי תנאים באחת ממטבחי העולם?

תן קצת פרטים.

 

[Eyal]

פארמה לאב? עוד חברה מפוקפקת שאין לה אבא ואמא ומיוצרת בארץ בתתי תנאים באחת ממטבחי העולם?

תן קצת פרטים.

עד כה 8 אנשים ניסו , מתוכם 2 עברו בדיקות דם ובדקו. וכולם חווים את אותה ההרגשה כמו שלקחו רפואי בסייקל קודם לו.

אז מה יכול להיות?

 

[SPF]

עד כה 8 אנשים ניסו , מתוכם 2 עברו בדיקות דם ובדקו. וכולם חווים את אותה ההרגשה כמו שלקחו רפואי בסייקל קודם לו.

אז מה יכול להיות?

קודם כל, כמו בחומרים שעכשיו אתה עושה יכול להיות גרוע מאוד. אבל נעזוב את זה.

אני לא מטריל, אני רוצה לדעת פרטים על החברה. מאיפה, מה, מי?
כי אני לא שמעתי על פארמה לאב. וגם יש הרגשה שכל חברה שניה קוראים לה או משהו עם פארמה - או משהו עם לאב.
שאף אחת מהם לא מיוצרת לא בתהליכים רפואיים ולא במעבדה.